Profile
3.99 -0.41(-9.23%)05/20/2024
Autolus Therapeutics plc (AUTL)
Autolus Therapeutics plc (AUTL)
Stock Exchange | United States (NASDAQ) |
Sector | Healthcare |
Industry | Biotechnology |
Type | Equity Shares |
CEO | Dr. Christian Martin Itin Ph.D. |
# of Employees | 463 |
Website | https://www.autolus.com |
CIK | 1730463.0 |
FIGI | BBG00KVT0685 |
Composite Ticker | AUTL:US |
Share Class FIGI | BBG00KVT06G6 |
Frist Price Date | 2018-06-22 |
Last Price Date | 2024-05-20 |
Business Description Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company''s clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom. |